In addition to her responsibilities as CEO, Ginger leads core assessment and strategic consulting engagements, with special emphasis on CNS-related categories. Previously, Ginger was the Director of Life Science Research at Chase Capital Partners (now CCMP Capital), a multi-billion dollar global private equity firm, where Ginger’s research and investment activities focused on high growth opportunities in new and emerging areas within the pharmaceutical, biotechnology and medical device industries. As Associate Director of the Center for Biotechnology at Northwestern University, Ginger helped to develop an innovative graduate program that combines the science and business of biotechnology. Ginger spent eight years in basic and applied scientific research, primarily in the field of Alzheimer’s disease, at the NIH and at Molecular Geriatrics, a start-up biotechnology company. Ginger has published multiple peer-reviewed articles and has been issued three patents. She earned her Bachelor of Science degree in Molecular Biology from University of Tennessee, a Doctorate in Molecular Biology from George Washington University in Washington, DC, and has completed graduate studies at the Kellogg Graduate School of Management at Northwestern University.
Communications’ Roda Muggeridge talks about the Cello Health family, and employees being supported to develop expertise in the areas in which they’re passionate.
Profile: Beth Fordham-Meier, VP Business Development, Cello Health BioConsulting
The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us todayContact us